A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01637246|
Recruitment Status : Completed
First Posted : July 11, 2012
Results First Posted : September 21, 2012
Last Update Posted : September 21, 2012
|Condition or disease||Intervention/treatment|
|Glaucoma, Open-Angle Ocular Hypertension||Drug: Any Fixed Combination Therapy|
|Study Type :||Observational|
|Actual Enrollment :||4385 participants|
|Study Start Date :||April 2009|
|Primary Completion Date :||November 2011|
|Study Completion Date :||November 2011|
POAG or OHT
Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
Drug: Any Fixed Combination Therapy
Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
- Change From Baseline in Intraocular Pressure (IOP) [ Time Frame: Baseline, 12 Weeks ]IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.
- Patient Assessment of Tolerability Using a 4-Point Scale [ Time Frame: 12 Weeks ]Patient assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The percentage of patients assessed as good and very good combined are reported.
- Physician Assessment of Tolerability Using a 4-Point Scale [ Time Frame: 12 Weeks ]Physician assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The percentage of patients assessed as good and very good combined are reported.
- Percentage of Patients Who Maintained Better Compliance With Treatment [ Time Frame: 12 Weeks ]Percentage of patients who maintained better compliance with treatment than prior therapy was assessed by the patient on a 3-point scale (better, equal, and worse compliance).
- Percentage of Patients Continuing on Therapy After 12 Weeks [ Time Frame: 12 Weeks ]Percentage of patients continuing on therapy after 12 weeks was assessed as Yes or No.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01637246
|Study Director:||Medical Director||Allergan|